Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022PRNewsWire • 02/04/22
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem CellsPRNewsWire • 02/03/22
Kintara Therapeutics announces multi-year research grant to support research of its VAL-083 program to treat glioblastomaProactive Investors • 01/12/22
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in GlioblastomaPRNewsWire • 01/12/22
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual ConferencePRNewsWire • 01/05/22
Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021PRNewsWire • 12/07/21
Kintara Therapeutics announces first international site activation in its Phase 2/3 clinical trial for glioblastoma multiformeProactive Investors • 11/30/21
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for GlioblastomaPRNewsWire • 11/30/21
Kintara presents updates on two Phase 2 clinical studies at the 2021 Society for Neuro-Oncology annual meeting.Proactive Investors • 11/18/21
Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual MeetingPRNewsWire • 11/18/21
Kintara Therapeutics boosts cash position in fiscal 1Q to $19.3M as it works on novel cancer therapiesProactive Investors • 11/15/21
Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 11/15/21
Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021PRNewsWire • 11/11/21
Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needsProactive Investors • 11/09/21
Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 09/29/21
Kintara Announces Closing of $15.0 million Offering Priced at a Premium to MarketPRNewsWire • 09/28/21